Our Pricing

Mounjaro vs Wegovy: Clinical Evidence Comparison

Published on: June 03, 2026

When evaluating mounjaro vs wegovy clinical evidence uk, understanding the head-to-head trial data is essential for making an informed treatment decision. Both medications are licensed by the MHRA for weight management, but their mechanisms, clinical outcomes, and side effect profiles differ significantly. Our UK pharmacists have analysed the published research to help you understand which option may suit your needs, subject to prescriber approval.

Understanding the Mounjaro vs Wegovy Clinical Evidence

Mounjaro (tirzepatide) and Wegovy (semaglutide) belong to the GLP-1 receptor agonist class, but tirzepatide uniquely activates both GIP and GLP-1 receptors, creating a dual-pathway mechanism [1]. This fundamental difference in pharmacology translates to measurably different clinical outcomes in published trials.

The landmark SURPASS-2 trial directly compared tirzepatide against semaglutide 1mg in adults with type 2 diabetes, demonstrating superior weight reduction with the highest tirzepatide dose [1]. Patients receiving tirzepatide 15mg achieved an average 12.4kg weight loss over 40 weeks, compared to 6.2kg with semaglutide 1mg — a statistically significant difference that has informed UK prescribing decisions.

For obesity-specific indications, the SURMOUNT-1 trial evaluated tirzepatide in adults without diabetes, showing average weight reductions of 15.0%, 19.5%, and 22.5% with 5mg, 10mg, and 15mg doses respectively over 72 weeks [2]. These results exceeded those seen in the STEP trials for semaglutide, which reported average reductions of 14.9% at the 2.4mg dose over 68 weeks [3].

Head-to-Head Trial Results: SURPASS-2 Analysis

The SURPASS-2 study remains the only published direct comparison of tirzepatide versus semaglutide, providing the strongest mounjaro vs wegovy clinical evidence available to UK prescribers [1]. This randomised controlled trial enrolled 1,879 adults with type 2 diabetes and elevated BMI, comparing three tirzepatide doses (5mg, 10mg, 15mg) against semaglutide 1mg over 40 weeks.

Primary endpoints included HbA1c reduction and body weight change. All three tirzepatide doses demonstrated superior efficacy for both outcomes, with the 15mg dose producing mean weight loss of 5.5kg more than semaglutide [1]. Importantly, 31.7% of participants on tirzepatide 15mg achieved at least 15% body weight reduction, compared to just 16.2% on semaglutide.

Safety profiles were comparable between treatments, with gastrointestinal side effects being the most commonly reported in both groups [1]. Nausea occurred in 17-22% of tirzepatide participants versus 18% with semaglutide, suggesting similar tolerability despite the enhanced efficacy observed with the dual agonist mechanism.

Statistical Significance and Clinical Relevance

The weight loss differences observed in SURPASS-2 were not only statistically significant (p<0.001) but also clinically meaningful [1]. A 5-10% body weight reduction is associated with improvements in cardiovascular risk factors, whilst reductions exceeding 15% can produce remission of obesity-related comorbidities such as sleep apnoea and fatty liver disease. The higher proportion of participants achieving this threshold with tirzepatide represents a tangible clinical advantage when selecting between treatments.

SURMOUNT vs STEP Trials: Obesity-Specific Evidence

For patients without diabetes seeking weight management, the SURMOUNT and STEP trial programmes provide the most relevant mounjaro vs wegovy clinical evidence. SURMOUNT-1 enrolled 2,539 adults with obesity or overweight plus weight-related comorbidity, excluding those with diabetes [2]. Participants received tirzepatide 5mg, 10mg, 15mg, or placebo alongside lifestyle intervention.

At 72 weeks, the tirzepatide 15mg group achieved mean weight reduction of 22.5% from baseline — the highest reported in any obesity pharmacotherapy trial to date [2]. By comparison, the STEP 1 trial of semaglutide 2.4mg reported mean reduction of 14.9% at 68 weeks [3]. Both trials used similar inclusion criteria and lifestyle intervention protocols, making this comparison particularly informative for UK prescribers.

Secondary endpoints further distinguished the treatments. In SURMOUNT-1, 55% of participants on tirzepatide 15mg achieved at least 20% weight loss, versus 35% in STEP 1 with semaglutide 2.4mg [2][3]. These proportions matter clinically, as greater weight loss correlates with more substantial improvements in cardiometabolic health markers including blood pressure, lipid profiles, and inflammatory biomarkers.

Side Effect Profiles: What the Clinical Evidence Shows

Gastrointestinal adverse events dominate the safety profiles of both medications, occurring in 60-80% of trial participants across studies [1][2][3]. Nausea, diarrhoea, vomiting, and constipation are the most frequently reported, typically emerging during dose escalation and diminishing over subsequent weeks.

In SURPASS-2, discontinuation rates due to adverse events were 4.3-6.2% across tirzepatide doses compared to 3.2% with semaglutide 1mg [1]. SURMOUNT-1 reported discontinuation rates of 4.3-6.2% with tirzepatide versus 2.6% with placebo [2], whilst STEP 1 showed 4.5% discontinuation with semaglutide 2.4mg [3]. These similar rates suggest comparable real-world tolerability despite tirzepatide's dual mechanism.

Serious adverse events occurred in fewer than 7% of participants across all trials, with no consistent pattern distinguishing tirzepatide from semaglutide [1][2][3]. Pancreatitis, gallbladder disorders, and hypoglycaemia (when combined with insulin or sulphonylureas) remain theoretical concerns with all GLP-1 receptor agonists, though incidence in clinical trials has been low. UK prescribers assess individual risk factors before initiating either treatment.

Managing Common Side Effects

Both medications employ gradual dose escalation protocols specifically designed to minimise gastrointestinal symptoms. Mounjaro typically starts at 2.5mg weekly for four weeks before increasing, whilst Wegovy begins at 0.25mg with monthly increments [4]. Patients who experience persistent nausea or vomiting should contact their prescriber, as dose adjustment or temporary hold may be appropriate. Adequate hydration and eating smaller, more frequent meals can help manage these effects during the initial weeks.

Long-Term Efficacy and Weight Maintenance Evidence

Sustaining weight loss beyond the initial trial period remains a critical consideration when evaluating mounjaro vs wegovy clinical evidence. Extension studies and real-world data provide insight into durability of effect with continued treatment.

The SURMOUNT-1 trial demonstrated continued weight reduction through 72 weeks, with no plateau observed in the final months [2]. Similarly, STEP 1 participants maintained their weight loss through 68 weeks of treatment [3]. However, withdrawal studies for both medications show rapid weight regain when treatment stops, underscoring that these are chronic disease therapies rather than short-term interventions.

The STEP 4 trial specifically examined weight maintenance with semaglutide, randomising participants who had already lost weight on the medication to either continue treatment or switch to placebo [5]. Those continuing semaglutide maintained their weight loss and lost additional weight, whilst the placebo group regained approximately two-thirds of lost weight over 48 weeks. Similar withdrawal patterns have been observed with tirzepatide, suggesting both medications require ongoing use to sustain benefits.

Choosing Between Mounjaro and Wegovy: Clinical Considerations

UK prescribers weigh multiple factors when recommending between these treatments, including baseline BMI, comorbidities, previous treatment response, and patient preference. The clinical evidence suggests tirzepatide produces greater average weight loss, but individual response varies considerably.

Cost considerations also influence treatment selection. At Cured Pharmacy, Mounjaro is available from £124.99 following clinical assessment, whilst treatment costs and individual circumstances will be discussed during your consultation with a UK prescriber. Both medications require ongoing weekly injections, though patient preference surveys suggest similar acceptability for both delivery devices.

Patients with type 2 diabetes may particularly benefit from tirzepatide's superior HbA1c reduction demonstrated in SURPASS trials [1]. Conversely, those seeking the most established safety record may prefer semaglutide, which has been available longer and has more extensive post-marketing surveillance data. Your UK prescriber will assess your complete medical history, current medications, and treatment goals to recommend the most appropriate option for your individual circumstances.

Starting Your Treatment Journey

Both Mounjaro and Wegovy require a prescription from a UK-registered prescriber following clinical assessment. At Cured Pharmacy, our online consultation takes under three minutes and is reviewed by qualified UK clinicians. If approved, your medication is dispensed by our GPhC-registered pharmacy and delivered discreetly to your address. Regular follow-up consultations ensure safe dose titration and ongoing monitoring throughout your treatment journey.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., Brown, K. D., SURPASS-2 Investigators. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., SURMOUNT-1 Investigators. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
3. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., STEP 1 Study Group. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Summary of Product Characteristics: Mounjaro 2.5 mg solution for injection in pre-filled pen. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/ [accessed 13 August 2026]
5. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., STEP 4 Investigators. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Weight loss outcomes depend on adherence to prescribed treatment and lifestyle modifications.